Treatment of Childhood Kaposiform Hemangioendothelioma With Sirolimus

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which his been used extensively in children following solid organ transplantation has been demonstrated to have anti angiogenic activity in pre clinical models Limited experience suggests that it may have application to the treatment of vascular lesions We describe our experience with a 1 year old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0 1 mg/kg/day) This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions Pediatr Blood Cancer 2010 55 1396-1398 (C) 2010 Wiley Liss Inc